I'll start by reading the PDF, then check recent developments relevant to its claims.

Let me read the rest of the document.

I've got the book's structure (5 parts, 14 essays, 2000–2017) and its opening chapters. The PDF text is truncated by the reader, but the essays are on HedWeb, so I can spot-check specifics. Let me first verify fast-moving facts that affect the book's claims.

I have solid grounding on the fast-moving facts. Let me spot-check a few of the book's fact-dense essays on HedWeb to anchor essay-specific suggestions.

I now have what I need on Parts I, III and V. Let me verify three remaining specific claims before writing up the memo.

Verified. Now let me load the Canvas skill and prepare the editorial memo as a working document.

Now I'll write the editorial memo as a canvas document.

The memo is ready. Let me also make a small note in Personal Knowledge so future conversations on this book project have context.

I've prepared a full editorial memo in the canvas — "Suggested Updates & Corrections: Can Biotechnology Abolish Suffering? (2nd edition)" — organised as factual corrections, updates by part, and structural suggestions. The highlights:

Factual corrections

• Suicide toll: the book's "over 800,000" (Abolitionist Project) and "almost a million" (High-Tech Jainism) should become WHO's current figure of more than 720,000 deaths/year, now the third leading cause of death among 15–29-year-olds ( WHO).
• The Shakespeare citation is transposed: the toothache quote is Much Ado About Nothing, Act V, Scene i — the book prints "Scene Five, Act One".
• The 5-HTTLPR claim needs replacing: the Caspi-style "short allele → 80% depression after 3 negative life-events" finding failed large-scale replication (Border et al., 2019); the COMT and ADA2b "pessimism gene" citations are the same pre-GWAS story. The heritable-set-point argument survives — recast it with GWAS evidence (102 depression variants in 807,553 individuals; Howard et al., 2019) ( Nature Neuroscience).
• Smaller fixes: ~20,000 protein-coding genes (not 25,000), sequencing now under ~$200 (the "$10 genome" forecast didn't materialise), soften the quadriplegia "full adaptation" claim to "substantial but incomplete", and temper the oxytocin/mirror-neuron passage.

Biggest content updates since 2017

• CRISPR is clinical reality: first approved CRISPR therapy (CASGEVY, UK world-first Nov 2023; US Dec 2023; expanded to children 2+ in 2026) ( HCPLive) — plus He Jiankui's 2018 germline editing as the reproductive revolution's dark first act, and the Jo Cameron FAAH-OUT case as a real-world "benign allele".
• LLMs are the major omission: Parts IV–V predate the entire LLM era. A second edition should engage the Butlin/Long expert report on AI consciousness ( arXiv) and the 2025 Cogitate adversarial results, where IIT fared poorly ( Nature) — arguably your "zombie" prediction about non-sentient verbal intelligence is now vindicated and worth saying so explicitly.
• Part III refresh: cultivated meat is approved but commercially stalled; Burkina Faso halted the Target Malaria gene-drive trial in Aug 2025 ( Innovation Report); Colossal's dire wolves (April 2025) prove large-predator genome editing works ( Phys.org), though the mammoth timeline is slipping ( Time); and the forest elephant picture has changed ( WWF).

Structural suggestions: a second-edition preface, new essays (digital sentience, FAAH-OUT, de-extinction), new objections in Appendix I ("AI risk makes it moot", "value lock-in"), a glossary and index, and a URL sweep of Additional Resources — plus scattered copy fixes ("we are are", "the eve an era").

I've also saved a short project note so future conversations on the book have this context: No access.